PharmaEngine, Inc. (TPEX:4162)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
55.10
+1.30 (2.42%)
Apr 28, 2026, 1:30 PM CST
-37.32%
Market Cap 7.92B
Revenue (ttm) 911.42M
Net Income (ttm) 387.64M
Shares Out 143.68M
EPS (ttm) 2.69
PE Ratio 20.48
Forward PE 19.96
Dividend 2.00 (3.72%)
Ex-Dividend Date Aug 13, 2025
Volume 422,130
Average Volume 369,189
Open 54.10
Previous Close 53.80
Day's Range 53.60 - 55.50
52-Week Range 53.00 - 93.70
Beta 0.25
RSI 37.05
Earnings Date May 12, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 45
Stock Exchange Taipei Exchange
Ticker Symbol 4162
Full Company Profile

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.

Financial Statements

News

There is no news available yet.